Your session is about to expire
← Back to Search
Hypofractionated Radiotherapy for Cancer (RT-PACE Trial)
RT-PACE Trial Summary
This trial is testing whether delivering more radiation over a shorter time period is more effective in treating cervical or endometrial cancer with fewer side effects.
RT-PACE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRT-PACE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 107 Patients • NCT03324802RT-PACE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My doctor decides if I need chemotherapy along with radiation.It's been over 16 weeks since my hysterectomy, but I had chemotherapy before starting radiotherapy.I had a hysterectomy for cervical or endometrial cancer.I haven't been diagnosed with any cancer other than skin, breast, bladder, or cervical cancers in the last 2 years.I have a history of inflammatory bowel disease.I can take care of myself but might not be able to do heavy physical work.My cancer originates from the cervix or endometrium, including non-epithelial types and early-stage adenocarcinoma.My cancer has not spread to distant parts of my body, confirmed by scans.I have recovered from previous cancer treatment side effects, or they are mild.I have had radiation therapy to my abdomen or pelvis before.I am 18 years old or older.
- Group 1: Treatment (hypo-fractionated radiotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any openings for volunteers to join this research at present?
"According to the data posted on clinicaltrials.gov, this trial is still enlisting participants. The initial posting occurred on 11th November 2021 and was last revised on 1st March 2022."
What is the sampling size of this research project?
"Affirmative. According to the clinicaltrials.gov website, enrollment is open for this experiment which was initially advertised on November 11th 2021 and last modified on March 1st 2022. 64 volunteers must be recruited from a single medical center."
What is the primary objective of this clinical trial?
"The primary purpose of this trial, which will be conducted over Baseline to week 3 of pelvic radiotherapy, is to assess the efficacy of hypofractionated radiotherapy. Auxiliary objectives include assessing financial toxicity with a Comprehensive Score for Financial Toxicity, making use of Decision Regret Scale and looking at changes in Functional Assessment of Cancer Therapy-Cervix (all using 90% confidence intervals)."
Share this study with friends
Copy Link
Messenger